I was born in Maryland but lived up north very briefly before my family moved to Nashville, TN, which is where I’ve spent most of my life, enjoying 50⁰ winters and drinking sweet tea. I’ve been fascinated by science for as long as I can remember, reading books on animal behavior, psychology, and anything else I could get my hands on. I attended Belmont University, majoring in Biology with a Premed emphasis. As a part of the Honors Program, we were required to write a thesis and this was what introduced me to the wonders of scientific research. I wanted to explore this career path instead of medicine and so I decided to pursue a Master’s degree at Lipscomb University. Under the guidance of Dr. Beth Conway, I was able to bolster my research experience by studying the role of the endothelin axis in invasive breast cancer. After graduating, I knew I wanted to do research and that brought me to Case Western and Dr. Keri’s lab, where I feel ideally positioned to contribute to our understanding of breast cancer and development.
Current Research Activities
- Identifying a novel gene or regulator important in early mammary morphogenesis
- Overcoming Palbociclib resistance in luminal breast cancers
- 6/2018 - 6/2020: T32, Molecular Therapeutics Training Program, Case Western Reserve University School of Medicine, Cleveland, OH
- 6/2018 - 6/2019: Social Coordinator, BGSO, Case Western Reserve University School of Medicine, Cleveland, OH
- 5/2018 - Present: Keri Lab Website Admin, Case Western Reserve University School of Medicine, Cleveland, OH
- 3/2018: Judge, Elementary Science Olympiad, Case Western Reserve University, Cleveland, OH
- 12/2017: Judge, Solon Middle School Science Fair, Solon, OH
- Halaka M, St. John H, Hired ZA, Rutledge GE, Do JM, DeMarco R, Majmudar PR, et al (in press). Endothelin Receptor expression and function in breast cancer cell invasion. Scientific Reports.
- Stephen HM, Khoury RJ, Majmudar PR, et al. Epigenetic suppression of neprilysin regulates breast cancer invasion. Oncogenesis. 2016; 5(3). doi:10.1038/oncsis.2016.16.